OQS
RLMD icon

Occudo Quantitative Strategies’s Relmada Therapeutics RLMD Stock Holding History

Occudo Quantitative Strategies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,941
Closed -$68.8K – 1133
2023
Q3 		$68.8K Hold
22,941
– – 0.01% 901
2023
Q2 		$56.4K Sell
22,941
-16,219
-41% -$44.8K 0.01% 956
2023
Q1 		$88.5K Sell
39,160
-91,551
-70% -$316K 0.01% 825
2022
Q4 		$456K Buy
+130,711
New +$1.15M 0.05% 530
2021
Q2 		– Sell
-5,708
Closed -$201K – 1024
2021
Q1 		$201K Sell
5,708
-1,007
-15% -$35.2K 0.04% 623
2020
Q4 		$215K Buy
+6,715
New +$231K 0.07% 528

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Occudo Quantitative Strategies's RLMD Position: Q4 2023 in Review

Occudo Quantitative Strategies sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 22,941 shares — an estimated $68.8K sold.

Occudo Quantitative Strategies first reported a position in RLMD in Q4 2020 and held it in 6 quarters. The position peaked at $456K in Q4 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Occudo Quantitative Strategies reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 22,941 Relmada Therapeutics shares in Q4 2023, an estimated $68.8K.
  • Occudo Quantitative Strategies first reported a position in Relmada Therapeutics in Q4 2020 and held it in 6 quarters.
  • Occudo Quantitative Strategies's Relmada Therapeutics position peaked at $456K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.